An Exciting New Era in the Treatment of Myeloproliferative Neoplasms

Oncology & Hematology Review (US)
doi 10.17925/ohr.2016.12.02.71
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Touch Medical Media, Ltd.

Related search

New Classification for Myeloproliferative Neoplasms

Cancer Discovery
Oncology
2018English

1. Pathophysiology and Treatment Strategies of Myeloproliferative Neoplasms

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
Medicine
2019English

Relevance of Weight Loss, Splenomegaly, and Hypocholesterolemia in the Treatment of Myeloproliferative Neoplasms— Implications for a JAK2 Inhibitor Era

Oncology & Hematology Review (US)
2011English

New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape

Clinical Cancer Research
Cancer ResearchOncology
2016English

Ruxolitinib Treatment and Risk of B‐cell Lymphomas in Myeloproliferative Neoplasms

American Journal of Hematology
Hematology
2019English

Histological Evaluation of Myeloproliferative Neoplasms

Journal of clinical and experimental hematopathology : JCEH
Medicine
2018English

Effective Treatment of Low-Dose Decitabine in Myelodysplastic Syndrome/Myeloproliferative Neoplasms

OncoTargets and Therapy
OncologyPharmacology
2017English

DNMT3A Mutations in Myeloproliferative Neoplasms

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

Italian Survey on Clinical Practice in Myeloproliferative Neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party Initiative

American Journal of Hematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy